| Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review MSC Li, KKS Mok, TSK Mok Annals of Translational Medicine 11 (10), 2023 | 28 | 2023 |
| Transbronchial techniques for lung cancer treatment: where are we now? JWY Chan, ICH Siu, ATC Chang, MSC Li, RWH Lau, TSK Mok, CSH Ng Cancers 15 (4), 1068, 2023 | 12 | 2023 |
| EGFR testing in paraffin-embedded cell block cytology material is reliable with increased detection for effusion fluid JKM Ng, C Chow, RCK Chan, KP Chan, JJX Li, MSC Li, KF To Lung Cancer 174, 97-103, 2022 | 10 | 2022 |
| Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference LS Chan, J Liu, MSC Li, L Li, Q Tao, TSK Mok Clinical Epigenetics 15 (1), 36, 2023 | 6 | 2023 |
| Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non–Small Cell Lung Cancer KWC Lee, MSC Li, W Gai, YM Lau, AKC Chan, OSH Chan, CK Lee, ... JAMA oncology 9 (2), 261-265, 2023 | 5 | 2023 |
| Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease MSC Li, KWC Lee, KKS Mok, HHF Loong, KC Lam, FST Mok, LL Chan, ... JTO Clinical and Research Reports 5 (4), 100648, 2024 | 3 | 2024 |
| Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC SPL Saw, YF Low, GGY Lai, LL Chan, WKY Wong, G Tsui, OH Chen, ... Lung Cancer 193, 107856, 2024 | 2 | 2024 |
| 1349P Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases M Li, K Mok, LL Chan, KWC Lee, HHF Loong, KC Lam, F Mok, YM Lau, ... Annals of Oncology 34, S776-S777, 2023 | 2 | 2023 |
| Review on endobronchial therapies—current status and future JWY Chan, ICH Siu, ATC Chang, MSC Li, RWH Lau, TSK Mok, CSH Ng Annals of Translational Medicine 12 (4), 75, 2023 | 2 | 2023 |
| SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant AHK Cheung, KY Wong, SL Chau, F Xie, Z Mui, GYH Li, MSC Li, J Tong, ... Pathology 56 (4), 504-515, 2024 | 1 | 2024 |
| Clinical application of liquid biopsy genomic profiling in NSCLC: Asian perspectives MSC Li, KKS Mok, LL Chan, TSK Mok The Journal of Liquid Biopsy 3, 100131, 2024 | 1 | 2024 |
| CNS outcomes of osimertinib plus chemotherapy in patients with EGFR mutation positive lung cancer beyond osimertinib progression WKY Wong, KKS Mok, GPC Tsui, OH Chen, HHF Loong, LL Chan, K Yan, ... Clinical Lung Cancer, 2025 | | 2025 |
| Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer SPL Saw, WZ Zhong, R Fu, MSC Li, Y Goto, SB Fox, Y Yatabe, BH Ong, ... Lung Cancer, 108076, 2025 | | 2025 |
| Germline Human Leukocyte Antigen Status is Associated With Immunotherapy-Induced Pneumonitis and Treatment Response in Patients With Non–Small Cell Lung Cancer With High … AHK Cheung, Z Mui, WW Yeung, C Chow, FY Mandy, OH Chen, KY Wong, ... JTO Clinical and Research Reports 6 (1), 100754, 2025 | | 2025 |
| Next-generation immunotherapy: igniting new hope for lung cancer MSC Li, ALS Chan, KKS Mok, LL Chan, TSK Mok Therapeutic Advances in Medical Oncology 16, 17588359241302021, 2024 | | 2024 |
| Osimertinib-Related QTc Prolongation: Real-World Incidence and Impact of Drug Dosing on Recurrence Risk OH Chen, WKY Wong, KKS Mok, LL Chan, C Tang, MSC Li Clinical Lung Cancer 25 (8), 738-743. e2, 2024 | | 2024 |
| Receptor tyrosine kinase fusion-mediated resistance to EGFR-TKI in EGFR-mutant NSCLC: a multi-center analysis and literature review Y Xia, K Wang, J Zhao, Z Arter, Y Zhang, J Zhou, Y Lu, L Zeng, R Du, ... Journal of Thoracic Oncology, 2024 | | 2024 |
| Tracking Progression of EGFR Mutation Positive NSCLC From Blood: Is This the Prime Time? SYM Liu, MSC Li Journal of Thoracic Oncology 19 (11), 1482-1485, 2024 | | 2024 |
| Anti-CTLA-4 in non-small-cell lung cancer: insights from the NIPPON study MSC Li, SPL Saw, A Addeo The Lancet Respiratory Medicine 12 (11), 840-842, 2024 | | 2024 |
| Can therapeutic drug monitoring of lorlatinib help us design the right CROWN? M Li, RA Soo Lung Cancer 196, 2024 | | 2024 |
